Modelling optimized investment approach for Uzbekistan by Duric, Predrag et al.
Sustainable Financing of National HIV Responses
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 
Getting to Zero
Modelling an Optimised Investment 
Approach for Uzbekistan 
THE REPUBLIC OF UZBEKISTAN
This publication is not copyrighted and may be reproduced without prior 
permission, but with appropriate reference to the source.
The inputs provided by the UNDP research team members to the content, 
analysis, opinions and recommendations contained in this publication do not 
necessarily reflect the views of the United Nations Development Programme 
(UNDP).
Design and layout by Phoenix Design Aid A/S, Denmark.  
ISO 14001/ISO 9000 certified and approved CO2 neutral company –  
www.phoenixdesignaid.com
Tashkent, 2015
Modelling an Optimised Investment 
Approach for Uzbekistan 
Sustainable Financing of National HIV Responses
Contact to the research team and authors:
Dr. Christoph Hamelmann
Regional Team Leader
HIV, Health and Development
UNDP Regional Hub Europe and the CIS
christoph.hamelmann@undp.org
Contact:
Dr. Nurmat Satiniyazovich Atabekov
Director of Republican Centre to Fight AIDS and 
Coordinator of the Multisectoral Expert Council
uzbekspid@minzdrav.uz
Abbreviations .............................................................................................................................................6
Acknowledgments ....................................................................................................................................7
Foreword .....................................................................................................................................................8
Executive summary ...................................................................................................................................9
1.  Why is this document needed? ...................................................................................................11
The HIV response is heavily dependent on international sources ..................................................................11
The current HIV response is insuﬃcient to meet all commitments ...............................................................11
International aid is unlikely to increase ............................................................................................................................11
Objectives ...........................................................................................................................................................................................11
2.   How much is spent? Where does the money come from? ......................................................13
The national HIV response has been dependent on international aid ........................................................13
Breakdown of funding by programme components..............................................................................................13
3.   What are the results of current investments? ...........................................................................17
Investments have averted infections ................................................................................................................................17
HIV prevalence is declining, but slowly ............................................................................................................................17
HIV testing high, but needs further improvement ...................................................................................................17
Treatment coverage: depending on the way of calculation – but too low ..............................................17
Treatment needs continue to rise .......................................................................................................................................18
4.   Scenario 1: Maintaining the current investment allocations and budget level,  
what will the HIV epidemic look like by 2020? .........................................................................19
HIV incidence and prevalence are expected to decline slowly ........................................................................19
HIV transmission mode shifting from injecting towards sexual .......................................................................19
Number of PLHIV eligible for ART is expected to increase with guideline update ..............................20
Return on investment – Scenario 1: ‘Maintaining 2012 investment allocations and  
budget level’......................................................................................................................................................................................21
5.   Scenario 2: What can be improved by optimising efficiencies under the current  
budget envelope? ..........................................................................................................................22
More value for money through technical eﬃciency ...............................................................................................22
More value for money through allocative eﬃciency ..............................................................................................22
 Background for allocative eﬃciency .........................................................................................................................22
 Methods for allocative eﬃciency ................................................................................................................................22
 Modelling results for allocative eﬃciency .............................................................................................................23
Improved impact – but still insuﬃcient service coverage ...................................................................................25
Return on investment – Scenario 2: ‘Optimising the investment allocations under  
2012 budget level’ .........................................................................................................................................................................26
Table of Contents
MODELLING AN OPTIMISED INVESTMENT APPROACH FOR UZBEKISTAN4
6.   Scenario 3: Fulfilling the commitments for people in need – the rights-based  
investment case ..............................................................................................................................27
Shortfalls of the current and optimised investment case under the current budget ceiling ........27
Modelling the scale-up to universal coverage of essential HIV services .....................................................27
 Background on universal coverage ...........................................................................................................................27
  Methods for modelling universal coverage of essential HIV prevention, treatment 
 and care services ...................................................................................................................................................................28
 Modelling results for a rights-based investment case approach ............................................................28
Return on investment – scenario 3: ‘Scaling up to universal coverage by 2020 ....................................29
7.   Rights-based investment today – the highest impact now and in the future ....................30
The rights-based investment approach – highest impact on HIV infections and DALYs  
in the short-term ............................................................................................................................................................................30
The rights-based investment approach – highest impact on HIV infections and DALYs  
also in the long-term ...................................................................................................................................................................30
8.   Remarks ...........................................................................................................................................32
Annex .........................................................................................................................................................34
Annex 1. Model description ..................................................................................................................34
Overview of analytical methods...........................................................................................................................................34
Relationships between spending and risk behaviours ..........................................................................................38
Counterfactual scenarios ..........................................................................................................................................................38
Cost-eﬀectiveness calculations for past evaluations ...............................................................................................39
Future impact of HIV programmes and optimal allocation of resources....................................................40
Annex 2. Data inputs ...............................................................................................................................41
Summary of costs and unit costs .........................................................................................................................................41
SUSTAINABLE FINANCING OF NATIONAL HIV RESPONSES 5
 
Abbreviations
AIDS  Acquired immunodeficiency syndrome
ART  Antiretroviral therapy
DALY Disability-adjusted life year
GF  Global Fund to Fight AIDS, 
Tuberculosis and Malaria
HIV Human immunodeficiency virus
HR Human resources
HTC HIV testing and counselling
LRF Low-risk females
LRM Low-risk males
MDG Millennium Development Goal
MSM Men who have sex with men
NFM New funding model (of the GF)
OI Oportunistic infections 
OVC Orphans and vulnerable children
PLHIV People living with HIV
PMTCT  Prevention of mother-to-child 
transmission
PWID People who inject drugs
RAC Republican Centre to Fight AIDS
SDG Sustainable development goal
STI Sexually transmitted infection
SW Sex workers
MODELLING AN OPTIMISED INVESTMENT APPROACH FOR UZBEKISTAN6
Acknowledgements
Predrag Đurić, Christoph Hamelmann (UNDP Europe and the Commonwealth of Independent States, 
RBEC), David P. Wilson and Cliff Kerr (University of New South Wales, Sidney, Australia) were the lead 
authors.
Christoph Hamelmann and Predrag Đurić developed the document structure, figures, tables and 
scenarios in discussions with the country team and in consultations with peer experts. They were also 
facilitating the data collection and data quality assurance with the country team, and wrote the main 
body of the document.
David Wilson and Cliff Kerr developed and ran the mathematical model, and wrote the main body of the 
technical model descriptions in the Annex of the document.
This publication builds on the inputs and reviews of the Uzbekistan country team working on the  
development of an HIV investment case for Uzbekistan: Nurmat Satiniyazovich Atabekov (RAC),  
Umida Islamova (Centre for Economic Research), Zakir Kadirov, Liya Perepada (UNDP Uzbekistan),  
Flora Sallikhova, and on the coordination with Roman Hailevich, Jean-Elie Malkin and Manoela Manova 
from the regional UNAIDS office in Moscow.
Many others have participated in reviews of drafts, data verification and translations, among them 
Lusine Aydinyan, Victoria Froltsova, Alisher Juraev, Alexandra de Olazarra, Sophia Sul, Alexander Steven 
Wahn, Julia Whitman and Karen Zhang. The study would not have been possible without the valuable 
comments and support from John Macauley and Boyan Konstantinov (both from the regional UNDP HIV, 
Health and Development Team, RBEC).
Financial support was provided by UNDP through the Unified Budget, Results and Accountability 
 Framework and co-sponsoring from the Russian Federation. 
SUSTAINABLE FINANCING OF NATIONAL HIV RESPONSES 7
 
Owing to the National Strategic Programmes to Fight 
HIV / AIDS in the Republic of Uzbekistan that are 
implemented in the country since 2003, and reinforcing 
strong commitment of the Government to reduce the 
burden of the disease among the country’s population, 
comprehensive prevention and treatment activities are 
being implemented to stabilize the epidemiological 
situation in the country.
The implementation of the Strategic Programme 
to Fight HIV for 2007-2011 was supported by the 
leadership of the country through the President’s 
Resolution dated December 2008 that regulates 
financial allocations and organization of HIV 
prevention and treatment programmes in the country. 
In order to implement the Resolution, the National 
Action Plan for 2009-2011 has been developed with 
increased state budget allocations embedded: The 
Republican Centre to Fight AIDS and all its branches 
in 14 administrative territories of the country have 
been equipped with modern diagnostic and laboratory 
equipment to ensure increased HIV testing and 
counselling services available for all. Important to note 
that along with these initiatives, enhancement of the 
normative and legislative work concerning HIV/ AIDS 
are ongoing.
A lot has been achieved in the area of HIV prevention 
and treatment, however it is important to understand 
what lies ahead for the country and what should be 
done in order to stop the spread of the infection in the 
country and the whole region. I hope that this report 
will greatly contribute towards achieving this goal. 
Nurmat Atabekov
Director Republican Centre  
to Fight AIDS
Republic of Uzbekistan
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Foreword
{  The new SDG 31 calls for ending the HIV/AIDS 
epidemic by 2030 and the provision of universal 
access to essential health services, including HIV 
prevention and treatment services, thereby re-
enforcing the UNAIDS Getting-to-Zero Strategy 
and the fast track approach for upscaling such 
services from current coverage levels2,3. 
{  While considerable progress has been made, 
Uzbekistan is still struggling to reverse the spread of 
HIV/AIDS, key populations at higher risk for HIV 
exposure still face discrimination and criminalization, 
and ART coverage is well below the MDG6 target. 
{  As a low middle-income country, Uzbekistan’s 
national HIV response is still dependent on external 
funding, mainly provided through the Global Fund 
to Fight AIDS, TB and Malaria (GF). Demands are 
increasing for higher domestic funding as pre-
condition for external support, and while there is a 
renewed commitment to scale up the HIV response 
under the new Strategic Programme for Fighting 
HIV Infection in the Republic of Uzbekistan, for 
2013-2017 of the Republic of Uzbekistan4 external 
funding is rather stagnating at current levels. 
{  This report aims to contribute to the development 
of sustainable financing strategies for the national 
HIV response in the short-, mid-, and long-term 
perspective by modelling the impact of alternative 
investment approaches. As part of the short-term 
1  United Nations, General Assembly. Transforming our world: the 2030 
Agenda for Sustainable Development. New York: United Nations, General 
Assembly; 2015.
2  Joint United Nations Programme on HIV/AIDS. Getting to Zero: 
2011–2015 strategy. Geneva: Joint United Nations Programme on HIV/
AIDS; 2010.
3  Joint United Nations Programme on HIV/AIDS. Fast-Track: ending the 
AIDS epidemic by 2030. Geneva: Joint United Nations Programme on 
HIV/AIDS; 2014.
4  Republic of Uzbekistan. Strategic programme for fighting HIV infection in 
the Republic of Uzbekistan for 2013-2017. Tashkent: Government; 2012.
contribution, the report provides a rational for 
improved allocative efficiency that can be used for 
the GF concept note under the GF New Funding 
Model (NFM). 
{  For the modelling, the following key questions of 
primary relevance for investment decisions related 
to the national HIV response were identified and 
addressed through modelling three investment 
scenarios using 2012 as the reference year: 
 P  What is the HIV epidemic in Uzbekistan 
likely to look like if the response continues 
unchanged? And what will be the return on 
investment by 2020? 
Scenario 1: Continue with the current 
investment allocations and current budget 
ceiling
 P  Can be more achieved with the same amount 
of resources, and how? What would then be the 
return on investment by 2020?
Scenario 2: Continue with optimised 
investment allocations and current budget 
ceiling
 P  Using optimised efficiencies, what would need 
to be done and how much would it cost to 
achieve universal coverage of the key prevention 
and treatment services? What would then be the 
return on investment by 2020? 
Scenario 3: Continue by scaling up to 
universal coverage of essential HIV prevention 
and treatment services
SUSTAINABLE FINANCING OF NATIONAL HIV RESPONSES 9
Executive summary
 P  For all three scenarios, what would be the long-
term impact by 2030?
The model results suggest:
 P  Maintaining the current investment allocations 
and budget level should be the absolute 
minimum target in order not to fall back behind 
the impact the national HIV response has 
achieved so far. 
 P  Technical and allocative efficiencies can be 
improved and recommendations are provided 
in the report. However, the current budget 
ceiling is too low to achieve universal coverage 
of essential HIV services. Due to the resulting 
rationalization, only improving efficiencies 
without addressing the overall budget 
constraints (scenario 2) will not be sufficient 
in Uzbekistan for ‘Getting-to-Zero’, ending the 
HIV/AIDS epidemic by 2030 and fulfilling the 
basic rights for access to essential HIV services 
for those in need.
 P  To achieve these goals and targets (scenario 3) 
the overall investment until 2020 would need to 
be increased by about 40% in order to achieve 
universal coverage for all essential HIV services.
 P  As return on the investment, around 103,000 
new HIV infections would be averted between 
2014 and 2030 under scenario 3 using the ‘test 
and treat’ approach (around 91,000 using WHO 
2013 guidelines, 88,000 using 2012 national 
guidelines). Scenario 2 and 1 avert significantly 
lower numbers of HIV infections, approximately 
70,000 and 65,000, respectively.
 P  In addition, about 870,000 DALYs would be 
averted between 2014 and 2030 under scenario 
3 using the ‘test and treat’ approach (822,000 
using WHO 2013 guidelines, 796,000 using 
2012 national guidelines). Scenario 2 and 1 avert 
significantly less DALYs, approximately 516,000 
and 430,000.
 P  Despite the significantly higher number of 
HIV related deaths averted under scenario 3, 
the model predicts for this scenario the lowest 
number of PLHIV by 2030.
 P  Detailed information about the mathematical 
model used is provided in the Annex.
The key message of this report: 
With a moderate increase of the investment volume until 2020 combined with an optimised 
investment allocation the national HIV response in Uzbekistan can be brought on a trajectory which 
fulfils the basic rights to access to all essential HIV services for those in need and makes ending 
the epidemic threat of HIV/AIDS in Uzbekistan a realistic goal if an environment without stigma 
and discrimination is provided so that services available will be accepted and used by the affected 
communities.
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The HIV response is heavily dependent 
on international sources
{ Uzbekistan is a lower-middle income country. 
While some components of Uzbekistan’s economy 
have increased substantially, the government is 
aiming for further improvements in a number of 
regional and global indicators.
{ The Uzbekistan government has exercised 
leadership in financing substantial parts of its 
HIV response at a sustained level in recent years. 
However, the national HIV response is still 
dependent on international sources, particularly 
from the GF.
The current HIV response is 
insufficient to meet all commitments
{ People in Uzbekistan continue to be at substantial 
risk of HIV infection, related morbidities and 
mortality.
{ HIV prevention and treatment do not cover 
all those in need, and not all internationally 
recommended HIV service components are being 
provided.
{ HIV incidence and prevalence in Uzbekistan seem 
largely to stabilize. Model-based estimates suggest 
that both incidence and prevalence are slowly 
declining among most key populations at higher 
risk of HIV exposure although with significant sub-
national differences5, but remain relatively stable 
among the populations with lower risk.
5  Republic of Uzbekistan. Analysis of HIV infection triangulation data in the 
Republic of Uzbekistan. Tashkent: Ministry of Health of the Republic of 
Uzbekistan; 2015. For example, HIV prevalence among PWID in Tashkent 
city is 24.5%, compared to 7.3% at the national level, HIV prevalence 
among SWs is above 5% in eight regions compared to 2.1% at the national 
level
International aid is unlikely to 
increase
{ The recent global economic crisis has diminished 
the prospects of growing or even stable 
international funding for national HIV responses in 
the region.
{ Changing eligibility and co-financing requirements 
under the NFM of the GF − which provides 
primary support for key prevention, treatment 
and care programmes in Uzbekistan − underlines 
the importance of sustainability strategies for the 
national HIV/AIDS response.
{ External funders are increasingly supporting 
countries to establish transitional funding 
mechanisms from international to domestic 
sources.
Objectives
{ To provide model estimates of future epidemic 
trajectories in the context of the development of 
an HIV/AIDS investment case and sustainable 
financing strategies of the national response for 
Uzbekistan under three scenarios:
 P  Scenario 1: Continue with the current 
investment allocation and current budget 
ceiling;
 P  Scenario 2: Continue with optimised investment 
allocation and current budget ceiling;
 P  Scenario 3: Continue by scaling up to universal 
coverage of essential HIV prevention and 
treatment services. 
 2012 was used as the reference year.
{ To estimate and compare the programme costs and 
the impact (‘return on investment’ expressed in new 
HIV infections averted and DALYs averted) of the 
three scenarios above in the mid-term (2020) and 
long-term (2030) perspective under consideration 
of short-term objectives such as the development 
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1.  Why is this document needed?
of GF concept note under the NFM, and long-term 
objectives such as the UNAIDS ‘Getting to Zero’ 
goals6, ‘Together we will end AIDS’ campaign7 and 
the ‘End of HIV/AIDS Epidemic’ target by 2030 
proposed for the SDGs8.
6  Joint United Nations Programme on HIV/AIDS. Getting to Zero: 
2011–2015 strategy. Geneva: Joint United Nations Programme on HIV/
AIDS; 2010.
7  Joint United Nations Programme on HIV/AIDS. Together we will end 
AIDS campaign.
8  Joint United Nations Programme on HIV/AIDS. Fast-Track: ending the 
AIDS epidemic by 2030. Geneva: Joint United Nations Programme on 
HIV/AIDS; 2014. United Nations General Assembly. Transforming our 
world: the 2030 Agenda for Sustainable Development – Draft resolution 
referred to the United Nations summit for the adoption of the post-2015 
development agenda by the General Assembly at its sixty-ninth session. 
New York: United Nations General Assembly; 2015.
12 MODELLING AN OPTIMISED INVESTMENT APPROACH FOR UZBEKISTAN
The national HIV response has been 
dependent on international aid
{ $ 18.3 million9 and $ 23.9 million were invested 
in the HIV/AIDS response in Uzbekistan in 2011 
and 2012, respectively. HIV funding from the 
international community has increased, and has 
surpassed domestic spending in 2012. However, 
domestic spending has previously dominated and 
has remained stable (figure 1).
{ Overall investments in HIV/AIDS increased 
significantly between 2011 and 2012 due to 
increased international spending.
{ The GF has been the major international funder. Its 
share increased and accounted for about 75% ($ 10 
million) of the international funding in 2012. For 
the period 2014-2016, the GF has allocated $ 27.7 
9  All financial values in this report, including tables and figures, are 
expressed in United States dollars.
million for HIV grants in Uzbekistan10 making the 
annual average less than the funding level in 2012.
Breakdown of funding by programme 
components
{ Approximately 49% of all HIV/AIDS funding has 
been allocated to prevention (figures 2 and 3a).
{ Among prevention interventions the largest 
amounts were allocated to biomedical safety and 
key populations at higher risk for HIV exposure 
(figures 3b and 4).
{ Among the key populations, funding for targeted 
prevention was largest for PWID and much less for 
SW and MSM. However, funding for PWID did not 
10  Global Fund to Fight AIDS, Tuberculosis and Malaria. Global Fund 
Country Allocations: 2014-2016. Geneva: Global Fund to Fight AIDS, 
Tuberculosis and Malaria; 2014.
2.   How much is spent? Where does the 
money come from?
Figure 1: HIV funding in Uzbekistan in 2011 and 2012 by source*
*  National spending on HIV/AIDS in Uzbekistan was examined by major funding sources with the use of national statistics, sector reports, and data reported by 
public health service institutions for the years 2011 and 2012. Standard accountancy estimation methods were used to generate a complete dataset of national 
spending on HIV/AIDS spending.
Funding
TOTAL
$ 0 
$ 2,000,000 
$ 4,000,000 
$ 6,000,000 
$ 8,000,000 
$ 10,000,000 
$ 12,000,000 
2011 2012 
Government $ 10,950,865 $ 10,340,456 
Global Fund $ 5,932,645 $ 10,138,162 
Other international  $1,379,651 
$ 18,263,161
$ 3,395,444 
$ 23,874,062
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include opioid substitution therapy. PMTCT was a 
relatively small component of the total budget.
Approximately 49% of all HIV/AIDS 
funding has been allocated to prevention
{ There was an average annual spending on 
prevention of $ 47.89 per PWID, $ 19.33 per 
MSM, and $ 31.05 per SW (based on estimates 
of 45,000 PWID, 21,000 SW, and 8,000 MSM11). 
11  Based on the survey on 5 regions: Tashkent city, Tashkent region, 
Samarkand, region, Surkhandarya region, Andijan region (UNODS 
methodology); MSM population size estimated in the application for GF’s 
Rolling Continuation Channel.
These amounts are considerably less than what is 
required to meet international guidelines for these 
populations12.
{ Expenditure on care and treatment has increased 
substantially between 2011 and 2012 and reached 
almost 30% of the total budget (figures 2, 3a, 3c and 
4).
{ Overall programme management and human 
resources costs account for 21% of overall funding 
in 2011-2012.
12  The WHO, UNODC, UNAIDS technical guide for countries to set targets 
for universal access to HIV prevention, treatment and care for PWID 
(2012) indicates coverage in terms of sterile needle-syringes per PWID per 
year to be classified as low <= 100 <= mid <= 200 <= high; and coverage 
for opioid substitution treatment to be classified as low <= 20% <= mid 
<= 40% <= high. Similarly, the WB has invested in harm reduction 
programmes with indicated project targets of 200 needle-syringes per 
PWID per year and 240 condoms per SW per year. The funding required 
to meet these targets is substantially greater than current spending. The 
discrepancy for dedicated funding on prevention per MSM is even higher 
(Beyrer, Lancet 2012; Sullivan, Lancet 2012).
0% 
20% 
40% 
60% 
80% 
100% 
2011 2012 
Orphans and vulnerable children $ 110,000 $ 80,000 
Enabling environment $ 353,287 $ 425,018 
Human resources $ 91,162 $ 1,089,309 
Programme management $ 3,622,303 $ 3,129,274 
Care and tratment $ 3,979,459 $ 6,791,949 
Prevention $ 8,729,691 $ 9,750,606 
TOTAL $ 16,885,902 $ 21,266,156
Figure 2: HIV/AIDS funding in Uzbekistan in 2011 and 2012 by programme component*
* The budget breakdown data were only available for $ 16.9 out of 18.3 million for 2011 and $21.3 out of 23.9 million for 2012.
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a) b)
c) d)
Prevention 
49.4% 
Care and treatment 
28.8% 
Programme 
management 
18.0% 
Human resources 
3.2% 
Others 
0.6% 
HTC 
7.4% 
Youth 
3.5% 
PLHIV 
2.9% 
Sex workers 
6.7% MSM 
1.5% 
PWID 
24.8% 
PMTCT 
7.4% 
STI 
1.9% 
Biomedical safety 
43.3% 
Others 
0.6% 
 
Provider initiated
HTC 
12.7% 
ART 
45.3%  Lab monitoring 
11.3% 
 Others 
20.3% 
 OI prophylaxis and 
treatment 
10.4% 
Progamme
management 
78% 
Human resources 
11% 
Others 
11% 
Total budget for
2011-2012b
$ 38,042,058
($ 42,137,223) 
2011-2012 budget for
care and treatmentb
$ 10,771,408
2011-2012 budget
for preventionb
$ 18,480,297
2011-2012 budget for 
management and othersb
$ 8,900,253
Figure 3, a-d: Detailed HIV/AIDS funding allocations in Uzbekistan, 2011-2012*,**
*   National spending on AIDS in Uzbekistan was examined by major funding sources with the use of national statistics, sector reports, and data reported by 
public health service institutions for the years 2011 and 2012. Allocations to key populations are only referring to interventions specific for the respective key 
population at higher risk for HIV exposure (e.g. specific funding for key populations does not include their treatment or testing costs; on the other hand care 
and treatment includes care and ART for key populations).
**  The budget breakdown data were only available for $ 16.9 out of 18.3 million for 2011 and $21.3 out of 23.9 million for 2012.
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HOW MUCH IS SPENT? WHERE DOES THE MONEY COME FROM?
Figure 4: HIV/AIDS investment in Uzbekistan in 2011 and 2012 by target population and intervention type*
*  Allocations to key populations in figure 4 are only referring to interventions specific for the respective key population at higher risk for HIV exposure (e.g. 
specific funding for key populations does not include their treatment or testing costs; on the other hand care and treatment includes care and ART for key 
populations).
$ 0 
$ 1,000,000 
$ 2,000,000 
$ 3,000,000 
$ 4,000,000 
$ 5,000,000 
$ 6,000,000 
$ 7,000,000 
$ 8,000,000 
HTC Youth PLHIV SW MSM PWID STI PMTCT Care and 
treatment 
2011 $ 700,820  $ 282,975  $ 274,537  $ 162,032  $ 117,356  $ 2,430,912  $ 162,032 $ 690,646 $3,979,459 
2012 $ 675,820  $ 372,324  $ 255,056  $ 184,853  $ 154,657  $ 2,155,154  $ 184,853 $ 671,958 $6,751,949 
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Investments have averted infections
{ Modelling of the HIV epidemic in Uzbekistan 
confirms that if the prevention and treatment 
programmes had not been implemented, current 
HIV prevalence and incidence would be far greater, 
especially among PWID.
HIV prevalence is declining, but slowly
{ Current HIV prevention policies appear to be 
keeping HIV prevalence stable or declining in key 
populations, but still high and increasing in some 
regions among PWID and SW.
{ HIV prevalence among PWID is still high, but it has 
declined significantly from 19.7% in 2005 to 7.3% in 
2013 at national level, but it is considerably higher 
in certain parts of the country (e.g. in Tashkent city 
– 24.5%)13.
{ The prevalence among MSM is unclear – the most 
recent estimate of prevalence (3.3% in 2013) was 
very different from previous estimates (e.g. 6.8% 
in 2009, 0.7% in 2011) and there are uncertainties 
about the representativeness of these findings. 
Forecasts for the HIV epidemic among MSM are 
therefore difficult to make.
{ The prevalence among SW seems to be stable 
during the last several years, at around 2%, but still 
high is some regions14.
{ Modelling indicates that HIV prevalence may also 
slow down among intimate female partners of males 
who inject drugs. However, estimates of prevalence 
13  Republic of Uzbekistan. The results of epidemiological surveillance of HIV 
infection among people who inject drugs in 2013. Tashkent; 2014.
14  Republic of Uzbekistan. Analysis of HIV infection triangulation data in the 
Republic of Uzbekistan. Tashkent: Ministry of Health; 2015.
in the general lower-risk population are highly 
uncertain due to the lack of prevalence data.
HIV testing high, but needs further 
improvement
{ In 2012, RAC estimated that 66% of PLHIV were 
aware of their infection.
{ Many people are still diagnosed late, which results 
in late initiation of ART. This in turn leads to poorer 
clinical outcomes as well as longer and higher 
infectiousness due to uncontrolled viral load.
Some 34% of PLHIV are not aware of their 
infection
Treatment coverage: depending on 
the way of calculation – but too low
{ According to RAC estimates, there were 37,712 
PLHIV in Uzbekistan in 2012, of which 25,057 have 
been diagnosed. Of these 6,021 (16%) were on ART 
at the end of 2012, including 5,556 with suppressed 
viral load assuming standard compliance and drug 
efficacy15 (figure 5).
{ RAC estimated that about 13,350 PLHIV were 
eligible for ART in 2012 under the 2012 national 
guideline (according to model results). Estimates 
for ART coverage ranged therefore from 45% 
(6,021/13,350) to 74% (6,021/8,189) based 
on the 2012 national guideline and from 16% 
(6021/37,712) to 24% (6,021/25,057) based on the 
estimated and registered PLHIV, respectively. While 
15  Own model estimation.
3.   What are the results of current 
investments?
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ART treatment greatly improves a person’s quality 
of life, many PLHIV were still without treatment 
in 2012. Furthermore, the proportion of people 
on treatment is too small to have a significant 
preventive effect on HIV transmission at the 
population level.
Treatment needs continue to rise
16% of the estimated number PLHIV were 
on ART at the end of 2012
{ AIDS-related mortality is declining slowly.
{ The number of PLHIV requiring ART outstrips 
supply and is expected to increase further in the 
near future, including the need for second-line 
regimens.
{ In 2013 WHO released an integrated and 
consolidated ART guideline. The new 
recommendations are based on evidence that 
treating PLHIV earlier can both keep them healthy 
and lower the amount of virus in the blood, thus 
reducing the risk of onward infection. According 
to the 2013 guidelines ART should be initiated 
in adults living with HIV when their CD4 cell 
count falls to 500 cells/mm³ or less if not indicated 
otherwise on clinical grounds. This will increase the 
number of PLHIV eligible for ART considerably 
compared to the previous WHO guidelines and 
the 2012 national guideline in Uzbekistan which 
still recommends ART initiation at a CD4 count of 
350 cells/mm³ or less if not indicated otherwise on 
clinical grounds.
{ For 2014 and 2015, the Government has allocated $ 
2 million as part of the cost sharing agreement that 
helped to cover around 2,000 new patients in 2014 
and additional 2,015 new patients in 2015.
Figure 5: Treatment cascade for Uzbekistan in 2012*
*  Source: RAC (estimated number of PLHIV, number of PLHIV diagnosed and alive, number of PLHIV on treatment), own model estimation (number of PLHIV 
with suppressed viral load).
PLHIV diagnosed & alive on treatment with suppressed viral load
37,712 25,057 6,021 5,566 
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This chapter summarises key model outputs for the 
following questions: What is the HIV epidemic in 
Uzbekistan likely to look like if the response continues 
unchanged? And what will be the return on investment 
by 2020?
Scenario 1: ‘Maintaining the 2012 investment allocations and budget level’ 
HIV incidence is expected to decline 
slowly
{ The first HIV case in Uzbekistan was recorded in 
1987. However, before the 2000s, there was little 
known about HIV in Uzbekistan. By the end of 
2000 there had been a cumulative of 230 people 
diagnosed with HIV and officially registered which 
then increased to 31,864 at the end of 2012 of which 
25,057 were still alive.
{ For the future projection, the model-estimated 
annual HIV incidence shows a moderate decline 
from approximately 3,300 in 2012 to around 2,500 
in 2,020.
{ The projected declining incidence is driven by both 
key populations at higher risk for HIV exposure 
and general population; in SW incidence is 
projected to decline by 74%, in PWID by 22%, but 
also in low risk males (39%) and females (27%), 
while it is estimated that the incidence in MSM will 
increase by 14%.
HIV transmission mode shifting from 
injecting towards sexual
{ In 2012, 54.2% of newly diagnosed HIV infections 
were transmitted sexually, 31.8% through injecting 
drug use and 3.5% from mother to child. HIV 
will continue to be transmitted among PWID in 
Uzbekistan but the trend towards a larger share of 
sexual transmissions will progress (figure 6).
54.2% of newly diagnosed HIV infections 
were transmitted sexually in 2012
4.   Scenario 1: Maintaining the current 
investment allocations and budget level, 
what will the HIV epidemic look like by 2020?
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Number of PLHIV eligible for ART is 
expected to increase with guideline 
update
{ Proceeding with current investment allocations 
at the current budget level, the estimated number 
of PLHIV is projected to slightly decrease from 
around 37,000 in 2012 to 35,000 in 2020 (figure 7). 
{ The number of PLHIV eligible for ART is estimated 
to reach 19,200 in 2020 based on the 2012 national 
guideline, and 24,400 based on the WHO 2013 
guidelines.
Under scenario 1, 19,200 (24,400) PLHIV 
will be eligible for ART by 2020 under 
the current national (under WHO 2013) 
guideline
{ If testing rates are not increased, 14,200 PLHIV 
will go undiagnosed, representing about 40% of all 
PLHIV.
Since the total number of PLHIV on ART would 
slightly decrease because of budget constraints and 
the increasing number of second line ART, and 
since the model predicts the number of PLHIV to 
only slightly decrease, ART coverage in 2020 would 
remain low between 31% and 57%: 31% of the 
estimated number of PLHIV (11,000/35,000), 45% 
of PLHIV eligible for ART according to WHO 2013 
guidelines (11,000/24,400), 57% of PLHIV eligible 
for ART according to the 2012 national guideline 
(11,000/19,200). Following the 2012 national guideline 
(the WHO 2013 guideline) around 8,200 (13,300) of 
the PLHIV would be eligible but without ART; 5,100 
(10,300) of them would know their status and be on a 
waiting list for ART.
Figure 6:  Model-estimated trend in HIV incidence under Scenario 1  
(‘maintaining 2012 investment allocations and budget level’)
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Return on investment – Scenario 1: 
‘Maintaining 2012 investment 
allocations and budget level’
{ Compared to the counterfactual scenario of 
no HIV/AIDS programmes at all, ‘maintaining 
current investment allocations and budget ceiling’ 
would avert about 12,500 new HIV infections and 
49,000 DALYs until 2020 at a total programme 
cost of $167.1 million (2014 – 2020, not counting 
inflation).
Figure 7:  Estimated numbers of PLHIV, of PLHIV eligible for ART and of PLHIV on ART  
(Scenario 1 – ‘Maintaining 2012 investment allocations and budget level’)
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 SCENARIO 1: MAINTAINING THE CURRENT INVESTMENT ALLOCATIONS 
AND BUDGET LEVEL, WHAT WILL THE HIV EPIDEMIC LOOK LIKE BY 2020?
This chapter summarises key model outputs for the 
following questions: Can more be achieved with the 
same amount of resources, how can this be achieved 
and what would be the return on investment by 2020? 
Scenario 2: ‘Optimising the investment allocations at the 2012 budget level’ 
More value for money through 
technical efficiency
{ With the need to achieve more, with less funding, 
it is important to consider how unit costs can be 
reduced. If unit costs are reduced, more can be done 
with the same resources.
{ Overall programme management costs account 
for 18% of overall funding in 2011-2012. This is 
deemed to be generally acceptable.
{ Using the most efficient models of service delivery 
and removing barriers that limit the effectiveness 
and efficiency of service delivery, a 5% technical 
efficiency gain was considered as realistic for the 
model.
A 5% technical efficiency gain was 
considered realistic for the model
More value for money through 
allocative efficiency
Background for allocative efficiency
{ The resource allocation in Uzbekistan has to take 
into account the disease burden, the distribution 
among sub-populations and the potential for 
impact. There is an important opportunity to 
further improve the allocation of resources to the 
populations and programmes that will result in the 
greatest impact.
{ Allocative efficiency can be considered the 
allocation of resources in the best combination 
across various programme components that leads 
to optimal outcomes and impact within a defined 
budget envelope. It should be noted that allocative 
efficiency does not tell us how big the overall 
budget envelope (over time) should be. In addition, 
allocative efficiency is assessed here from the 
perspective of an individual disease programme, 
and not across the health sector or beyond. 
Methods for allocative efficiency
{ A formal mathematical optimisation procedure 
surrounded an epidemiological transmission 
model to calculate the allocations of funding across 
HIV programme components which is likely to 
result in the least number of new HIV infections 
and DALYs over the 2014-2020 period; it uses the 
2012 investment allocations as a starting point 
and keeps the budget constant on 2012 amounts 
(see table A2 in Annex for more details). The 
model was informed by available epidemiological, 
behavioural and clinical data, as well as likely 
programme outputs and other outcomes associated 
with possible funding combinations over all 
programmes.
5.   Scenario 2: What can be improved by 
optimising efficiencies under the current 
budget envelope?
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{ The most cost-effective interventions are those 
which have proven effectiveness in reducing risk 
behaviours and/or biological transmissibility, or 
improving survival and health, and are targeted 
to groups of people at greatest risk of acquiring 
or transmitting HIV. The optimisation procedure 
automatically factors these considerations into the 
calculation of ideal allocations taking into account 
costs and the level of effectiveness to meet a given 
objective.
Allocative efficiency is considered here 
as an optimal allocation mix to reach the 
objectives of minimizing new HIV infections 
and DALYs
{ There will be different optimal allocations for 
different objectives. For example, objectives could 
include: minimising the number of new infections 
with current resources; minimising the number of 
deaths with current resources; or minimising the 
amount of money required to achieve a certain 
percentage decline in new infections or to meet 
the targets of the National Strategic Plan, such as 
providing universal coverage for prevention and 
treatment services. 
{ Here, the initial objective is designed to reflect the 
UNAIDS ‘Getting to Zero’16 visions by minimising 
both DALYs (accounting for disease progression 
and death) and new HIV infections by 2020 with 
current (2012) resources. Each additional infection 
was considered equivalent to 20 DALYs, a value 
which takes into account both DALYs outside the 
window of the intervention period as well as the 
effect of subsequent infections. While the model 
is optimised for the period until 2030, the outputs 
are discussed in this chapter for the short- and 
mid-term period until 2020 to focus on the current 
programming needs under the GF new funding 
model in Uzbekistan.
16  UNAIDS ‘Getting to zero’ strategy for 2011-2015 has three visions: to get 
to zero new infections, to get to zero AIDS-related deaths and to get to zero 
discrimination.
The model assumes that ART reduces the 
probability of HIV transmission by 70%
{ The model takes into account the dual impact 
of ART: ‘treatment as prevention’17. It could be 
assumed that treatment reduces transmission risk 
by as much as 96% based on the HPTN-052 clinical 
trial setting (Cohen et al. NEJM 2011)18, but this 
may be an overestimation. In an observational 
cohort study of serodiscordant couples in China 
it was shown that HIV transmission was reduced 
by only 26% due to ART19. Based on a large review 
of literature we conducted across many settings, 
adherence to ART was estimated as 75% for the 
model; at 92-96% efficacy for full adherence, this 
weights to approximately 70% efficacy of ART 
in reducing infectiousness when accounting 
for observed adherence patterns. Therefore, we 
assumed that ART reduces transmission by 70%20. 
{ In the model, we kept biomedical prevention 
programme components (blood safety, safe medical 
injections and universal precautions), condom 
provision, community mobilization and prevention 
for PLHIV constant.
Modelling results for allocative efficiency
{ Current resource allocation strikes a compromise 
between an optimal incidence-reduction strategy 
and an optimal DALY-reduction strategy. Generally, 
it is considered that the allocation of resources 
across programme components in Uzbekistan is 
well balanced and close to optimal for minimizing 
HIV incidence and DALYs (with the exception of 
the unclear situation of MSM). However, there is 
17  World Health Organisation. Antiretroviral treatment as prevention (TASP) 
of HIV and TB. Geneva: World Health Organisation; 2012.
18  Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, 
Kumarasamy N, et al. Prevention of HIV-1 infection with early 
antiretroviral therapy. N Engl J Med. 2011;365:493–505.
19  Jia Z, Mao Y, Zhang F, Ruan Y, Ma Y, Li J, et al. Antiretroviral therapy to 
prevent HIV transmission in serodiscordant couples in China (2003-11): a 
national observational cohort study. Lancet. 2013;382:1195–203.
20  Regional studies on the impact of ART on preventing HIV transmissions 
in key populations at higher risk are not available; such studies would be 
useful to improve investment decisions.
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 SCENARIO 2: WHAT CAN BE IMPROVED BY OPTIMISING 
EFFICIENCIES UNDER THE CURRENT BUDGET ENVELOPE?
Figure 8, a, b:  Comparison of budget allocations under the current (2012) budget envelope; a) current (2012) 
allocations, b) optimised allocations*,**
a)  Current b)  Optimised
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*   Allocations to key populations in figure 8 are only referring to interventions specific for the respective key population at higher risk for HIV infection (e.g. 
specific funding for key populations does not include their treatment or testing costs; on the other hand care and treatment includes care and ART for key 
populations).
**  The budget breakdown data were only available for $ 16.9 out of 18.3 million for 2011 and $21.3 out of 23.9 million for 2012.
still some potential for refinement towards better 
allocative efficiency.
The current budget is insufficient to scale 
up essential HIV interventions to universal 
coverage, even under optimised efficiencies
{ It was identified that overall the current (2012) 
budget envelope is insufficient to scale up all 
effective standard interventions to achieve 
universal coverage. Therefore, the results for an 
optimised allocative efficiency for the currently 
underfunded programme must be interpreted with 
caution in the context of service rationalization 
under consideration of competing effectiveness of 
essential key interventions with regard to reduction 
of infections, disease burden and death.
{ With these constraints in mind, the model suggests 
only small changes for an optimised resource 
allocation under the 2012 budget constraints by 
shifting resources from general prevention among 
youth towards HTC and treatment (figure 8, table 1).
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Improved impact – but still 
insufficient service coverage
In late 2013 the Government of Uzbekistan committed 
$ 2 million in ART and other costs. Until June 2015, 
$ 894,697 was expended: $ 775,312 for procurement 
and delivery of ARV and $ 119,395 for CD4 and viral 
load tests. Taking this into account and adding it to 
the 2012 budget ceiling, modelling allocative efficiency 
results by 2020 in:
{ an estimated 36,000 PLHIV,
{ an estimated 19,000 of PLHIV eligible for ART 
based on the 2012 national guideline, and 24,000 
based on the WHO 2013 guidelines,
{ 10,500 PLHIV on ART (8,300 on the first-line 
and 2,200 on the second-line) with an estimated 
ART coverage of 55% among the estimated 
number of PLHIV eligible for ART according 
to the 2012 national guideline (10,500/19,000), 
44% (10,500/24,000) according to the WHO 2013 
guidelines and 29% among estimated number 
of PLHIV (10,500/36,000). About 5,000 (7,500) 
diagnosed PLHIV and eligible for ART would be 
without treatment access according to the 2012 
national guideline (WHO 2013 guideline).
Table 1:  Comparison of budget allocations under the current (2012) budget envelope: current (2012) 
allocation mix and optimised allocation*
Budget allocation in $
a) 2012 
allocation
b) optimised 
allocation
HIV spending TOTAL 21,266,156 21,266,156
Prevention SUBTOTAL 9,750,606 9,490,066
Prevention – biomedical safety, PLHIV prevention, other prevention 4,883,715 4,883,715
HTC 675,820 787,604
Prevention – SW 652,125 652,125
Prevention programmes for MSM 154,657 154,657
Harm reduction programmes for PWID 2,155,154 2,155,154
Prevention – youth 373,324 0
Prevention – STI 184,853 184,853
PMTCT 671,958 671,958
Care and treatment SUBTOTAL 6,791,949 7,052,489
Provider initiated testing and counselling 454,315 454,315
Care and treatment – ART, opportunistic infection prevention, lab. monitoring, others 6,337,634 6,598,174
Programme management and human resources SUBTOTAL 4,218,583 4,218,583
Others – OVC, enabling environment SUBTOTAL 505,018 505,018
* The budget breakdown data were only available for $ 16.9 out of 18.3 million for 2011 and $21.3 out of 23.9 million for 2012.
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  SCENARIO 2: WHAT CAN BE IMPROVED BY OPTIMISING 
EFFICIENCIES UNDER THE CURRENT BUDGET ENVELOPE?
Return on investment – Scenario 2:  
‘Optimising the investment 
allocations under 2012 budget level’
{ Compared to the counterfactual scenario of no 
HIV/AIDS programmes at all, ‘optimizing the 
current investment allocations under the current 
budget ceiling’ would avert about 13,000 new HIV 
infections and 74,000 DALYs until 2020 at a total 
programme cost of $174.1 million21 (2014 – 2020).
21  Additional $ 1 million annually from the Government included.
Figure 9:  Estimated numbers of PLHIV, of PLHIV eligible for ART and of PLHIV on ART (Scenario 2 – ‘Optimising 
the investment allocations at the 2012 budget level’)
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This chapter summarizes key model outputs for the 
questions: Using optimised efficiencies, how much 
would it take to achieve universal coverage of the key 
prevention and treatment services, and what would 
then be the return on investment by 2020? 
Scenario 3: ‘Scaling up to universal coverage by 2020’ 
Shortfalls of the current and 
optimised investment case under the 
current budget ceiling
{ The modelling results of scenario 1 and 2 clearly 
demonstrate the limitations of the current budget 
level: too many PLHIV will remain undiagnosed 
and without essential services, even under 
optimised allocative efficiency and reduced 
programme management and HR costs; the impact 
on HIV incidence and DALYs remains limited.
Keeping the current budget envelope means: 
too many PLHIV will remain undiagnosed 
and without essential services
{ ‘Doing more and better with less’ is an important 
call for continuous quality improvement and 
efficiency gains, but there is clearly a threshold 
below which a budget simply becomes insufficient 
to fully meet the objectives.
{ The current epidemic indicators, service coverage 
and the modelling forecast show that overall 
the HIV response is underfunded in Uzbekistan 
to meet its objectives of ‘getting to zero’ and of 
fulfilling the commitments for universal coverage of 
essential HIV services.
Modelling the scale-up to universal 
coverage of essential HIV services
Background on universal coverage
{ Commitment to universal coverage of HIV 
service in Europe and Central Asia is reflected in a 
number of declarations, including the 2004 ‘Dublin 
Declaration on Partnership to Fight HIV/AIDS 
in Europe and Central Asia’22, the 2004 ‘Vilnius 
Declaration on Measures to Strengthen Responses 
to HIV/AIDS in the European Union and in 
Neighbouring Countries’23, and the 2007 ‘Bremen 
Declaration on Responsibility and Partnership 
– Together Against HIV/AIDS’24. Uzbekistan is 
22  Dublin Declaration on Partnership to fight HIV/AIDS in Europe and 
Central Asia. Breaking the Barriers – Partnership to fight HIV/AIDS in 
Europe and Central Asia Conference; 2004, Feb 23-24; Dublin, Ireland.
23  Vilnius Declaration on Measures to Strengthen Responses to HIV/AIDS 
in the European Union and in Neighbouring Countries. Europe and HIV/
AIDS – New Challenges, New Opportunities Conference; 2004, Sept 17; 
Vilnius, Lithuania.
24  Bremen Declaration on Responsibility and Partnership – Together Against 
HIV/AIDS. “Responsibility and Partnership -Together Against HIV/AIDS” 
Conference; 2007, Mar 12-13; Bremen, Germany.
6.   Scenario 3: Fulfilling the commitments 
for people in need – the rights-based 
investment case
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one of 55 countries included in the monitoring of 
progress against the commitments of the Dublin 
declaration25. 
Without universal coverage of essential HIV 
services, ending the epidemic by 2030 will be 
unrealistic
{ The main goals of the Strategic Programme 
for Fighting HIV Infection in the Republic of 
Uzbekistan for 2013-2017 are to ensure the 
reduction of the spread of HIV in Uzbekistan and 
to ensure universal access to HIV prevention, 
treatment, care and support26.
{ Universal health coverage is one of the targets 
under the proposed Sustainable Development Goal 
for health and it plays a key role in the positioning 
of health in the post-2015 development agenda27.
{ Without universal coverage of key prevention 
and treatment services, the target of ending the 
epidemic of HIV/AIDS by 2030 under SDG 3 will 
be unrealistic28.
Methods for modelling universal coverage of 
essential HIV prevention, treatment and care 
services
{ Using the same model structure as described in the 
previous chapter and detailed in the Annex, the 
objective of a rights-based investment approach 
is to reach universal coverage of essential HIV 
prevention services and ART by 2020;
{ Starting at estimated service coverage for HTC, 
ART, PMTCT and special interventions for key 
25  European Centre for Disease Prevention and Control. Thematic report: 
Combined reporting – Monitoring implementation of the Dublin 
Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 
2012 progress report. Stockholm: European Centre for Disease Prevention 
and Control; 2013.
26  Republic of Uzbekistan. Strategic programme for fighting HIV infection in 
the Republic of Uzbekistan for 2013-2017. Tashkent: 2012.
27  World Health Organisation. Positioning Health in the Post 2015 
Development Agenda – WHO Discussion Paper. Geneva: World Health 
Organisation; 2012.
28  United Nations General Assembly. Transforming our world: the 2030 
Agenda for Sustainable Development – Draft resolution referred to the 
United Nations summit for the adoption of the post-2015 development 
agenda by the General Assembly at its sixty-ninth session. New York: 
United Nations General Assembly; 2015.
populations in 2012, the model assumed an 
approximately linear increase over time to reach 
universal coverage for the key prevention and ART 
services by 2020;
{ For ART services, the model investigated 
alternatively the following three options to 
determine universal coverage: 
Option A: 95% of diagnosed PLHIV and 
eligible for ART under the 2012 national 
guideline; 
Option B: 95% of diagnosed PLHIV and 
eligible for ART under WHO 2013 guidelines;
Option C: 95% of all diagnosed PLHIV (‘test 
and treat’ concept29);
{ For PMTCT, the objective of the modelling was to 
achieve 95% coverage; for harm reduction specific to 
PWID and special preventive service for other key 
populations an 80 % coverage of estimated need was 
used. For HTC the objective was that 80 % of key 
populations at higher risk would know their status. 
Modelling results for a rights-based investment 
case approach
With a rights-based investment approach  
the number of PLHIV on ART would 
increase 5 to 6-fold
{ To achieve universal treatment access under 
scenario 3 option C (‘test and treat’) the number of 
PLHIV on ART would need to reach around 25,800, 
for option B (WHO 2013 guideline) approximately 
29  Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV 
elimination by ‘test and treat’ in hyperendemic settings. AIDS. 
2010;24(5):729-35.
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23,300 and for option A (2012 national guideline) 
about 20,000 by 2020. This reflects a 5- to 6-fold 
increase to 2013 ART figures.
{ Since coverage for PMTCT services is already high 
they would see only modest scale-ups by 2020, same 
as for harm-reduction programmes for PWID with 
the exception of opioid substitution therapy which 
is currently not being offered.
Return on investment –  
scenario 3: ‘Scaling up to universal 
coverage by 2020’
{ Under the assumption of the universal coverage for 
key preventive interventions, the epidemic impact 
would depend on the applied criteria for ART 
eligibility, as shown in table 2. 
Table 2:  Projected estimated epidemiological impact and programme costs* (point estimates) using three 
options** for ART eligibility criteria for Scenario 3: ‘Scaling up to universal coverage by 2020’
Universal ART coverage
By 2020 Option A Option B Option C
Estimated PLHIV 39,586 38,755 33,799
Estimated new HIV infections averted*** 20,270 21,150 26,818
Estimated DALYs averted*** 222,622 229,149 232,061
Total programme costs 2014-2020 210,619,371 228,104,257 248,786,151
*  2014-2020, not accounting for inflation.
**  See narrative for further explanation of option A, B and C.
***  Compared to the counterfactual scenario of no HIV/AIDS programmes at all.
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 SCENARIO 3: FULFILLING THE COMMITMENTS FOR PEOPLE 
IN NEED – THE RIGHTS-BASED INVESTMENT CASE
This chapter summarises key model outputs for the 
long-term impact until 2030 of scenario 1 (‘maintaining 
the 2012 investment allocations and budget level’), 
scenario 2 (‘optimising the investment allocations at 
the 2012 budget level’) and scenario 3 (‘scaling up to 
universal coverage’).
The rights-based investment 
approach – highest impact on HIV 
infections and DALYs in the short-term
{ In the previous chapters, model predictions showed 
the highest impact for scenario 3 ‘scaling up to 
universal coverage’ in terms of averting new HIV 
infections and DALYs by 2020; this is also the only 
scenario fulfilling international commitments 
made and core objectives of the National AIDS 
Programme. Comparisons of projected impact and 
costs are summarized in table 3.
The rights-based investment 
approach – highest impact on HIV 
infections and DALYs also in the  
long-term
{ The long-term impact of scenario 3 until 2030 is 
even more impressive; figure 10 shows comparisons 
of all scenarios.
{ Under scenario 3, the estimated number of PLHIV 
would be around 35,000 by using the 2012 national 
guideline, approximately 33,000 using WHO 2013 
treatment guideline, and about 23,000 using the 
‘test and treat’ approach. This compares to an 
estimated 33,000 PLHIV for scenario 2 and 35,000 
for scenario 1 (figure 10a). Differences can be 
explained by long-term dynamics of differences in 
averted HIV infections and averted HIV-related 
deaths.
{ An estimated cumulative total of about 103,000 
new HIV infections would be averted between 
2014 and 2030 under scenario 3 using the ‘test 
and treat’ approach (around 91,000 using WHO 
2013 guidelines, 88,000 using the 2012 national 
guidelines. The differences are mainly caused by the 
higher impact in earlier years through options with 
7.   Rights-based investment today – the 
highest impact now and in the future
Table 3:  Cumulative new HIV infections averted, cumulative DALYs averted and total programme costs under 
the three different scenarios (2014-2020)
Scenario 1 Scenario 2 Scenario 3
Option A*
Scenario 3
Option B*
Scenario 3
Option C*
New HIV infections averted 12,869 13,151 20,270 21,150 26,818
DALYs averted 49,218 74,110 222,622 229,149 232,061
Total programme costs $ 167.1 million $ 174.1 million $ 210.6 million $ 228.1 million $ 248.8 million
*  Option A: 95% of diagnosed AND eligible PLHIV by 2020, 2012 national guideline; option B: 95% of diagnosed AND eligible PLHIV by 2020, WHO 2013 
guidelines; option C: 95% of all diagnosed PLHIV by 2020 (“test and treat”).
MODELLING AN OPTIMISED INVESTMENT APPROACH FOR UZBEKISTAN30
more inclusive eligibility criteria for ART. Scenario 
2 and 1 achieve significantly lower numbers of 
averted HIV infections, approximately 70,000 and 
65,000, respectively (figure 10b).
{ Between 2014 and 2030 about 870,000 DALYs 
would be averted under scenario 3 using the ‘test 
and treat’ approach 822,000 using WHO 2013 
guidelines, 796,000 using 2012 national guidelines). 
For new HIV infections averted, the differences 
are mainly caused by the higher impact during the 
earlier years through options with more inclusive 
eligibility criteria for ART. Scenario 2 (516,000) and 
scenario 1 (430,000) avert about half the number of 
DALYs.
Figure 10 a-c:  Long term comparisons (2015-2030) of the epidemiological impact of scenario 1, 2 and 3;  
a) estimated number of PLHIV, b) estimated number of new HIV infections averted, and  
c) estimated DALYs averted
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 RIGHTS-BASED INVESTMENT TODAY – THE 
HIGHEST IMPACT NOW AND IN THE FUTURE
All mathematical models have their limitations and 
results should therefore be interpreted with the 
necessary caution. In particular, the following points 
should be considered:
{ All model forecasts are subject to uncertainty. 
Therefore, point-estimates indicate trends rather 
than exact figures. 
{ The model calibration depends as much on the 
quality of input data as on the quality of the model 
itself. The country and study teams including the 
RAC paid much attention to assure data quality 
and completeness. However, there is room for 
improvement for further studies, both in terms of 
data quality as well as for further improvements of 
the model structures. 
{ The best model calibration will rarely achieve an 
exact match of historical data, but mirror as closely 
as possible the key trends of them.
{ Modelling the optimization of allocative efficiencies 
depends critically on the availability of evidence-
based parameter estimates of the effectiveness and 
cost-efficiency of individual intervention packages 
or intervention components.
{ Particularly interventions related to the so-called 
critical enablers30 such as interventions against 
punitive laws and discrimination, community 
mobilization, but also interventions related to 
health systems strengthening often lack ‘hard’ 
effectiveness data in relation to the key impact 
indicators such as new HIV infections or DALYs 
averted. Under resource constraints like the 
scenario 2, the model will therefore suggest to 
reduce or even stop such interventions which 
30  United Nations Development Programme, Joint United Nations 
Programme on HIV/AIDS. Understanding and acting on critical enablers 
and development synergies for strategic investments. New York: United 
Nations Development Programme; 2012.
require to set model restrictions like fixing 
allocations to certain minimum amounts. 
{ Even for some of the more clinical interventions, 
the effectiveness in general but particularly in 
a specific country or population setting is less 
clear than commonly thought. Assumptions need 
therefore to be made in a transparent way so that 
they can be subject of discussion and review. One of 
the critical assumptions – the effectiveness of ART 
on HIV prevention – have been presented in detail, 
others are referred to in the Annex.
{ The model operates largely with current unit costs. 
Although the effect of increases or decreases of unit 
costs can be estimated with the model, the model 
itself cannot suggest what unit cost is adequate to 
achieve a defined standard of service quality or 
even what the defined standard should be. There is 
very little information about service quality and its 
contextual effect on impact available for Uzbekistan 
or for the region. This is an area which deserves 
much greater attention particularly in times in 
which funding mechanisms such as the new 
funding model of the GF structurally incentivise 
reduction of unit costs without having adequate 
quality monitoring measures in place.
{ Finally, no allocative efficiency optimization within 
a budget framework that is not sufficient to meet 
the needs for essential health services can replace 
the rights for basic health services. On the other 
hand, waste of resources under conditions of global 
resource constraints, low service coverage and 
inequities in service access make the fulfilment 
of these basic rights even more difficult. The key 
message of this document is therefore: With a 
moderate increase of the investment volume until 
2020 combined with an optimised investment 
allocation covering all essential HIV services 
the national HIV response in Uzbekistan can be 
brought on a trajectory which fulfils the basic 
8.  Remarks
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rights to access to essential HIV services for those 
in need and makes ending the epidemic threat 
of HIV/AIDS in Uzbekistan a realistic goal if an 
environment without stigma and discrimination is 
provided so that services available will be accepted 
and used by the affected communities.   
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Annex 1. Model description
Overview of analytical methods
To assess HIV epidemic trends, resource needs, the 
cost-effectiveness of past programmes, and the impact 
of potential future programmes, we developed a 
detailed mathematical model of HIV transmission 
and disease progression, called the Projection and 
Evaluation Tool (Prevtool).
Prevtool is an flexible population-based HIV model. 
The basic disease progression implemented in the 
model is shown in figure A1. This is the only aspect of 
model structure that is fixed, and specifies it as being an 
HIV model instead of a universal epidemic model.
In contrast to most other HIV models, the population 
groups used in Prevtool are not fixed. Instead, up to 
14 user-defined population groups may be used. A 
typical example for a concentrated HIV epidemic, such 
as used in Uzbekistan, is shown in figure A2. Here, 
five population groups are used, including low-risk 
(‘general’) males and females, SW, PWID and MSM.
Data are entered into Prevtool by means of an Excel 
spreadsheet, as shown in figure A3. Data entry is 
flexible, allowing everything from a separate data point 
for every population for each year, or a single data 
point for all populations over the entire time period.
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Figure A1: Schematic diagram of model structure*
*  Each compartment represents a single population group with the specified health state, while each arrow represents the movement of individuals between health 
states. All compartments except for ‘Susceptible’ represent individuals living with HIV. ‘Death’ includes all causes of death.
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The model uses a coupled system of ordinary 
differential equations to track the movement of people 
between health states. The overall population is 
partitioned in two ways: by group and by health state. 
Individuals are assigned to a given population based 
on their dominant risk; however, to capture important 
cross-modal types of transmission (e.g., SW becoming 
infected via injecting drug use), relevant behavioural 
parameters can be set to small but nonzero values (e.g., 
male PWID occasionally engage in commercial sex; 
MSM occasionally inject drugs).
The rate at which uninfected individuals in each 
population group become infected is determined by the 
force-of-infection for that population. This depends on 
the number of risk events an individual is exposed to 
in a given period of time and the infection probability 
of each event. Sexual transmission risk depends on 
the number of people in each HIV-infected stage (that 
is, the prevalence of infection in the population of 
partners), the average number of casual, regular, and 
commercial homosexual and heterosexual partnerships 
per person, the average frequency of sexual acts per 
Figure A2:  Population groups and interactions in 
Prevtool, example
Figure A3: Example of data entry spreadsheet for a concentrated epidemic
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Testing rate per 
year Тестирование 
(Количество 
протестированных 
и доля в ….)  
Low-risk males (Мужчины  с 
низким риском) 
Direct FSW (Прямые работники 
секс-бизнеса женщины)
Male low-risk PWID Мужчины 
ПИНы с низким  риском
Low-risk females (Женщины с 
низким риском)
25.00% 44.00% 31.00% 32.30%
Indirect FSW (Непрямые 
работники секс-бизнеса 
женщины)
Clients of FSW Клиенты 
работников секс-бизнеса 
MSM (МСМ) 18.00% 34.00% 30.70% 27.00%
Bisexual MSM (Бисексуальные 
МСМ)
Transgender (Трансексуалы)
Male high-risk PWID Мужчины 
ПИНы с высоким риском 36.40% 28.70% 30.00%
Female high-risk PWID Женщины 
ПИНы с высоким риском
Female low-risk PWID Женщины 
ПИНы с низким риском
High-risk males Мужчины  
(высокий риск) 
High-risk females Женщины 
(высокий риск) 
AIDS stage (стадия СПИДа)
Treatment rate per 
year Лечение 
(количество 
пролеченных и 
доля в …) в ГОД 
CD4(500) 0 0 0 0 0 0 0
CD4(350,500) 0 0 0 0 0 0 0
CD4(200,350) 200 820 1406 1520 2200 3552 5768
CD4(200) 15 108 164 235 263 301 253
Treatment failure 
(неэффективность лечения) 
0 0 0 115 143 123 112
No. of HIV 
diagnoses 
(Количество 
установленных 
диагнозов с ВИЧ)
Total (всего) 154 549 981 1836 2016 2198 2205 3167 3404 4016 3828 3584 3878 4247
General & 
migrant males
Clients of
Female SW
MSM
Male PWID
General & 
migrant females
Female SW
Female PWID
Heterosexual transmission
Injecting-related transmission
Homosexual transmission
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partnership, the proportion of these acts in which 
condoms are used, the efficacy of condoms, the extent 
of male circumcision, and the prevalence levels of STIs 
(which increase transmission probability) and HIV. 
The stage of infection (chronic, AIDS-related illness/
late stage, or on treatment) for the HIV-positive partner 
in a serodiscordant couple also influences transmission 
risk due to different levels of infectiousness in each 
infection stage. Intravenous transmission risk depends 
on the number of injecting partners per person per 
year, frequency of injecting per year, frequency of 
sharing injecting equipment and percentage of shared 
syringes that are cleaned before re-use and the efficacy 
of cleaning.
Mathematically, the force-of-infection is given by:
λ = 1−(1−β)n
where λ is the force-of-infection, β is the transmission 
probability of each event, and n is the effective number 
of at-risk events (thus n gives the average number 
interaction events with infected people where HIV 
transmission may occur). The value of the transmission 
probability β is based n average viral load of people 
in different stages of infection and transmissibility 
differs by mode of transmission (sharing of non-
sterile equipment for injected drug use, unprotected, 
heterosexual intercourse, and homosexual intercourse), 
and may be modified by behavioural interventions (for 
example, condom use or circumcision). The number 
of events n not only incorporates the total number 
of events, but also other factors that moderate the 
possibility that these events are capable of transmitting 
infection, such as condom use or circumcision. There is 
one force-of-infection term for each type of interaction 
(for example, casual sexual relationships between 
low-risk males and indirect female SW), and the force-
of-infection for a given population will be the sum of 
overall interaction types.
In addition to the force-of-infection rate, in which 
individuals move from uninfected to infected states, 
there are seven other means by which individuals may 
move between health states. First, individuals may die, 
either due to the background death rate (which affects 
all populations equally), due to injecting behaviour, 
or due to HIV/AIDS (which depends on CD4 count). 
Second, in the absence of intervention, individuals 
progress from higher to lower CD4 counts. Third, 
individuals can move from undiagnosed to diagnosed 
states based on their HIV testing rate, which is a 
function of CD4 count (for example, people with AIDS 
symptoms have a higher testing rate) and population 
type (for example, SW usually get tested more 
frequently than low-risk males). Fourth, diagnosed 
individuals may move onto treatment, at a rate which is 
dependent on CD4 count. Fifth, individuals may move 
from treatment to treatment failure, and sixth, from 
treatment failure onto second-line treatment. Finally, 
while on successful first- or second-line treatment, 
individuals may progress from lower to higher CD4 
count and they will have reduced infectiousness.
In total, the model can accommodate up to 294 
compartments (14 populations each with 21 health 
states), and the change in the number of people in 
each compartment is determined by the sum over 
the relevant rates described above multiplied by 
the compartments on which they act. For example, 
the number of individuals in the compartment 
corresponding to undiagnosed female sex workers with 
a CD4 count between 200 and 350 cells/µL changes 
according to the following equation:
where 350 −500 is the current population size of people 
with undiagnosed HIV and with a CD4 count between 
350 and 500 cells/μL, 200 −350   is the population size 
of the compartment with lower CD4 count (200-350 
cells/μL), τ is the disease progression rate for the given 
CD4 count, μ is the death rate, and η is the HIV testing 
rate. (Note: this example does not consider movement 
between populations, such as female SW returning to 
the low-risk female population and vice versa.) Each 
compartment (figure A1, boxes) corresponds to a 
single differential equation in the model, and each rate 
(figure A1, arrows) corresponds to a single term in that 
equation.
Most of the parameters in the model are related to 
calculating the force-of-infection; a list of model 
parameters is provided in table A1. Empirical estimates 
for model parameter values can be interpreted in 
Bayesian terms as prior distributions. The model must 
then be calibrated, which is the process of finding 
200 −350 = 350 −500 350 −500 − 200 −350 ( 200 −350 + 200 −350 + 350 −500 )
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posterior distributions of the model parameter values 
such that the model generates accurate prevalence 
estimates. Given the challenges inherent in quantifying 
all known constraints on the epidemic, initial 
calibration is performed manually, with oversight 
by and collaboration with in-country stakeholders 
where possible. This prior distribution is then used in 
a Monte Carlo Markov chain algorithm, which uses 
both epidemiological and behavioural data to calculate 
the log-likelihood for a given set of model parameters. 
The distribution of parameter values produced by the 
Monte Carlo Markov chain is the posterior, which 
is then used for all epidemiological and economic 
analyses. An example calibration is shown in figure A4.
Table A1: Input parameters of the model
Biological parameters Behavioural parameters Epidemiological parameters
Population parameters Background death rate Population sizes (TP)
HIV-related parameters Sexual HIV transmissibilities* (H)
STI-related transmissibility 
increase*
Condom eﬃcacy*
Circumcision eﬃcacy*
HIV health state progression 
rates (H)
HIV-related death rates (H)
Number of sexual partners* 
(TPS)
Number of acts per partner* (S)
Condom usage probability* (TP)
Circumcision probability* (T)
HIV prevalence (TP)
STI prevalence (TP)
Mother-to child transmission 
related parameters
Mother-to-child transmission 
probability
Birth rate
PMTCT access rate (T)
Injection-related parameters Injecting HIV transmissibility*
Syringe cleaning eﬃcacy*
Drug-related death rate
Number of injections* (T)
Syringe sharing probability* (T)
Syringe cleaning probability*
Methadone treatment 
probability (T)
Treatment parameters ART eﬃcacy*
ART failure rates
HIV testing rates (TPH) Number of people on ART (T)
Key: T = parameter value changes over time; P = parameter value depends on population group; H = parameter depends on health state; S = parameter depends on 
sexual partnership type; * = parameter is used to calculate the force-of-infection.
Figure A4: Calibration of Prevtool to Uzbekistan epidemic data*
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Relationships between spending and 
risk behaviours
In our analysis, we use a logistic/sigmoid function 
to describe the relationships between a behavioural 
parameter affected by a HIV prevention programme 
and the level of spending on that programme. Using 
this function with assumed uncertainties bounds, we 
obtain cost-outcome curve fits to available datasets 
for overall programme spending and associated 
behaviours. Indirect costs have no direct impact on 
HIV transmission parameters; but changes to HIV 
programmes may affect these costs to supply additional 
condoms, clean syringes, for example. Using these 
relationships, any change in HIV programme funding 
directly affects risk behaviours and changes to the HIV 
epidemic; an example of this is demonstrated in figure 
A5. The fitted cost-outcome relationships will represent 
the change in behaviours with spending.
Figure A5: Example of the relationship between spending on SW/client programmes and the HIV epidemic*
*Numerical values are for illustrative purposes only.
Counterfactual scenarios
Prevtool calculates the cost-effectiveness of past HIV 
programmes by comparing the expected number of 
new infections and AIDS-related deaths according 
to current and past conditions with the estimated 
numbers under counterfactual scenarios in the absence 
of funding for specific programmes.
We simulate counterfactual scenarios using 
Prevtool based on the assumed effect of the removal 
or enhancement of specific programmes. The 
calibrated simulations with the programmes in place 
represent the baseline scenario. For each prioritized 
population, we develop counterfactual scenarios for 
the behavioural parameters affected by prevention 
programmes prioritizing that population—with the 
parameters for the other populations remaining at 
their values obtained through the calibration process. 
Specific counterfactual scenarios used depend on the 
implementation and characteristics of HIV prevention 
programmes and the data available. We fit a logistic 
function to behavioural parameters affected by 
prevention programmes; figure A6 shows these cost-
outcome curves for Uzbekistan.
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Cost-effectiveness calculations for 
past evaluations
For each counterfactual scenario, we measure 
the health benefits of a specific HIV intervention 
programme in terms of HIV infections averted as well 
as life years and DALYs saved compared to the baseline 
scenario. We calculate incremental cost-effectiveness 
ratios (ICERs) to estimate the cost-effectiveness of 
each programme. These are calculated based on the 
counterfactual scenarios and comparing the spending 
of each programme (discounted annually), as well 
as estimated annual healthcare costs incurred/saved 
Figure A6: Cost-outcome curves for Uzbekistan
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(using unit health costs and utilities for each country 
obtained from our data synthesis), with the estimated 
effectiveness of the programmes. Determining whether 
a past HIV programme is cost-effective is dependent on 
country-specific thresholds. Appropriate thresholds for 
each country were determined after consultation with 
in-country stakeholders.
Future impact of HIV programmes and 
optimal allocation of resources
To investigate the potential impact of future HIV 
prevention programmes we run model projections 
for each scenario. Specific programme options are 
investigated but are based on core prevention methods 
(harm reduction), along with programmes based on 
using ART as prevention in combination with other 
programmes. We then compare projections where 
parameters and funding remain at current values 
and calculate the annual incidence, the number of 
infections averted, and the total cost required for each 
scenario.
Prevtool is used to determine the optimal allocation 
of funding using an adaptive stochastic linear 
gradient-descent optimization method. This calculates 
the allocation of funding to programmes with the 
minimum total infections, minimum prevalence, 
minimum AIDS-related deaths, or maximum DALYs 
saved. It is also possible to invert this analysis and 
calculate the minimum spend required to achieve a 
particular target in terms of one of those quantities.
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Annex 2. Data inputs
Summary of costs and unit costs
National spending on HIV/AIDS in Uzbekistan was 
examined by major funding sources with the use of 
national statistics, sector reports, and data reported 
by public health service institutions for the years 
2011 and 2012. Standard accountancy estimation 
methods were used to generate a complete dataset of 
national spending on AIDS. Costs were broken down 
by financing sources, agents, service providers, AIDS 
spending categories, and beneficiary populations 
using functional National AIDS spending assessment 
classifications and definitions. Data collection covered 
spending on AIDS response funded from domestic 
public and international funding sources.
Table A2: Budget for the national HIV programme by programme components
2011 budget in $ 2012 budget in $
HIV spending TOTAL* 16,775,902 21,266,156
Prevention SUBTOTAL 8,729,691 9,750,606
Condom provision 0 104,858
Community mobilization 1,200 2,550
HIV testing and counselling (HTC) 700,820 675,820
Prevention – youth in school 75,866 77,466
Prevention – youth out-of-school 207,109 294,858
Prevention of HIV transmission aimed at PLHIV 274,537 255,056
Prevention programmes for SW and their clients 594,493 652,125
Prevention programmes for MSM 117,356 154,657
Harm reduction programmes for PWID 2,430,912 2,155,154
Prevention, diagnosis and treatment of STI for general population 162,032 184,853
PMTCT not disaggregated by intervention 690,646 671,958
Biomedical safety 3,474,720 4,521,251
Care and treatment SUBTOTAL 3,979,459 6,791,949
Provider initiated testing and counselling 690,634 454,315
ART not disaggregated neither by age nor by line of treatment 2,900,447 5,216,777
Specific HIV-related lab monitoring 258,408 537,648
Psychological treatment and support service 129,970 153,156
Opportunistic infection outpatient prophylaxis and treatment 0 430,053
Orphans and vulnerable children SUBTOTAL 110,00 80,000
OVC social services and admin costs 110,000 80,000
Programme management SUBTOTAL 3,622,303 3,129,274
Planning, coordination and programme management 684,112 759,326
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Administration and transaction costs associated with managing and 
disbursing funds
63,296 333,996
Monitoring and evaluation 1,145,939 878,467
Serological-surveillance 0 134,689
Upgrading and construction of infrastructure 586,053 147,845
Programme management and admin not disaggregated by 
intervention
1,142,903 874,951
Human resources SUBTOTAL 91,162 1,089,309
Monetary incentives for HR not broken by staﬀ category 0 856,318
Training 91,162 232,991
Enabling environment SUBTOTAL 353,287 425,018
Advocacy 98,657 5,000
Human rights programmes 0 63,657
AIDS-specific institutional development 105,128 233,092
AIDS-specific programmes focused on women 0 63,657
Programmes to reduce gender-based violence 149,502 59,612
* Budget breakdown data were available for $16.9 million out of $18.3 million and $21.3 million out of $23.9 million for 2012 (data presented in figure 1).
Table A2: Budget for the national HIV programme by programme components (cont.)
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Table A9: Biological constants
Interaction-related transmissibility (% per act) Male & female (insertive) 0.09 (0.0001-0.1)
Male & female (receptive) 0.25 (0000.6-0.6)
Male & male (insertive) 0.02 (0.002-0.2)
Male & male (receptive) 0.02 (0.002-0.2)
Injecting 0.3 (0.1-1.0)
Mother-to-child 35.0 (20.0-50.0)
Disease-related transmissibility CD4(500) 4.0(1.2-5.0)
CD4(350,499) 1.0 (0.8-1.2)
CD4(200,349) 1.0 (0.8-1.2)
CD4(<200) 3.8 (3.6-4.0)
Treatment 0.2 (0.02-0.5)
Disease progression rate: (% per year) CD4 (500) to CD4 (350,499) 24.5 (22.6-26.4)
CD4 (350,499) to CD4 (200,349) 51.0 (47.0-55.0)
CD4 (200,349) to CD4 (<200) 51.0 (47.0-55.0)
Treatment recovery rate (% per year) CD4 (350,499) to CD4 (500) 45.0 (14.0-93.0)
CD4(200,349) to CD4 (350,499) 70.0 (29.0-111.0)
CD4 (<200) to CD4 (200,349) 36.0 (28.0-43.0)
Death rate (% mortality per year) Background 1.4 (0.9-2.0)
Injecting 1.0 (0.7-1.2)
CD4 (500) 0.052 (0.035-0.068)
CD4 (350,499) 0.128 (0.092-0.164)
CD4 (200,349) 1.1 (.0.2-2.0)
CD4 (<200) 50.0 (40.0-66.0)
Treatment (CD4<200) 4.0 (1.0-10.0)
Treatment failure rate (% per year) 1st-line 4.5 (3.0-6.0)
2nd-line 4.5 (3.0-6.0)
Eﬃcacy/change in transmissibility due to: Condom (%) 80.0 (60.0-99.0)
Circumcision (%) 60.0 (50.0-65.0)
Diagnosis (%) 30.0 (0.0-60.0)
STI cofactor increase (%) 700.0 (100.0-1000.0)
Syringe cleaning (%) 75.0 (70.0-80.0)
Methadone (%) 95.0 (90.0-99.0)
PMTCT (%) 78.0 (40.0-99.0)
Treatment risk compensation (%) 100.0 (95.0-200.0)
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Table A10: Partnerships
LRM LRF SW MSM PWID
Regular sexual interactions LRM 1 1
LRF
SW
MSM 1
PWID 1 1
LRM LRF SW MSM PWID
Casual sexual interactions LRM 1 1
LRF
SW
MSM 1
PWID 1 1
LRM LRF SW MSM PWID
Other sexual interactions LRM 1
LRF
SW
MSM 1
PWID 1
LRM LRF SW MSM PWID
Injecting interactions LRM
LRF
SW
MSM
PWID 1
Table A11: Transitions (% leaving per year)
LRM LRF SW MSM PWID
LRM
LRF
SW (20)
MSM
PWID
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